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2ABBREVIATIONS
AAV adeno-associated virus
ABL transforming gene of the Abelson murine leukaemia virus
Ad adenovirus
Ang angiopoietin
ATP adenosine triphosphate
CAR coxackie/adenovirus receptor
cDNA complementary deoxyribonucleic acid
CTFR cystic fibrosis transmembrane regulator
CUB complement-binding domain
DC dendritic cell
E embryonic day
EC endothelial cell
ECM extracellular matrix
EDA-ID ectodermal dysplasia with immunodeficiency
Egr-1 early growth response factor 1
ELC Ebstein-Barr virus-induced ligand for CCR7
ENU ethylnitrosourea
FGFR fibroblast growth factor receptor
FIGF c-fos-induced growth factor
FLK1 fetal liver kinase 1 (mVEGFR-2)
FLT1 fms-like tyrosine kinase 1 (VEGFR-1)
FLT4 fms-like tyrosine kinase 4 (VEGFR-3)
FOXC2 forkhead box C2
GDNF glial-derived neurothrophic factor
GIST gastrointestinal stromal tumor
HA hyaluronan
HR homology region
ICAM intercellular adhesion molecule 1
Ig immunoglobulin
IHC immunohistochemistry
JM juxtamembrane
kD kilodalton
KDR kinase insert domain containing receptor (hVEGFR-2)
KO knockout
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
KL KIT ligand
LEC lymphatic endothelial cell
LYVE-1 lymphatic vessel endothelial hyaluronan receptor 1
MAM meprin, A5, µ
MAPK mitogen-activated protein kinases
MEN multiple endocrine neoplasia
MET hepatocyte growth factor receptor
MFH-1 mesenchyme fork head 1
MIM Mendelian inheritance in man
MRI magnetic resonance imaging
mRNA messenger RNA
NRP neuropilin
PECAM-1 platelet endothelial cell adhesion molecule 1
PDGF platelet-derived growth factor
PlGF placenta growth factor
Prox1 prospero-related homeobox protein 1
PTB phosphotyrosine binding
RET rearranged during transformation
RTK receptor tyrosine kinase
Sema semaphorin
SH Src homology
SLC secondary lymphoid organ chemokine
Tek tunica interna endothelial cell kinase (Tie2)
Tie tyrosine kinase with Ig and epidermal growth factor homology domains
VEGF vascular endothelial growth factor
VEGFR VEGF receptor
VPF vascular permeability factor (VEGF)
VRF VEGF-related factor (VEGF-B)
VRP VEGF-related protein (VEGF-C)
WT wild-type
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4ABSTRACT
The discovery of the first lymphatic
endothelial specific receptor, vascular
endothelial growth factor receptor-3
(VEGFR-3) has facilitated studies on
lymphatic vessel formation and
regulation. According to recent studies,
VEGFR-3 is required for the
development of the blood vasculature
during embryogenesis. However,
VEGFR-3 becomes restricted to the
lymphatic endothelium, where its
signaling mediates proliferation,
survival and migration of lymphatic
endothelial cells (LECs). VEGFR-3 is a
receptor for two lymphangiogenic
growth factors, VEGF-C and VEGF-D.
Abnormal lymphat ic vessel
development and function are
associated with human lymphedema.
Lymphedema is characterized by
disfiguring and disabling swelling of the
limbs due to defective lymphatic
drainage. The molecular pathogenesis
of various lymphedema phenotypes
has been unclear, but recently,
missense mutations within the
VEGFR3 region were linked to primary
lymphedema. This study presents
functional characteristics of the
lymphedema-associated mutant
VEGFR-3s. In addition, a possible
treatment for lymphedema, with
VEGFR-3 as a target, is described.
We show here that missense
mutations of the VEGFR3 gene result
in lymphedema in several families.
During in vitro analysis of the mutant
receptors, all disease-associated
VEGFR3 alleles were found to encode
tyrosine kinase inactive proteins. The
ability of the mutant receptors to induce
downstream gene activation was
defective, and the mutant molecules
had longer cellular half-lives. These
results suggest that the mutant
VEGFR-3s interfere with the wild-type
(WT) receptor signaling and function in
a dominant negative manner,
consistent with the autosomal dominant
inheritance of primary lymphedema.
Thus, heterozygous loss of VEGFR-3
tyrosine kinase activity results in
human primary lymphedema.
Because the mutations within
VEGFR3  are likely to impair several
cellular processes, we have analysed
the pathogenesis of lymphedema using
the Chy mouse model. As in human
lymphedema patients, Chy mice have
an inactivating Vegfr3 mutation in their
germline, and swelling of the limbs due
to hypoplastic cutaneous lymphatics.
Lymphedema is the result of a
heterozygous genotype both in humans
and in the Chy mice, and thus there
remains some VEGFR-3 activity due to
the functional WT allele. We therefore
explored  the  possibility of using
VEGF-C  ligand  overexpression   as
a therapeutic tool for primary
lymphedema.  In  these  studies,
VEGF-C gene therapy induced growth
of functional cutaneous lymphatic
vessels in the Chy mice.
As a conclusion, this study
establishes  the  importance of
VEGFR-3 for normal lymphatic
vascular development, and that
mutations interfering with VEGFR-3
signal transduction are a cause of
primary lymphedema. Our results also
suggest that VEGF-C gene therapy
may be applicable to treatment of
human lymphedema.
5REVIEW OF THE LITERATURE
1 Development of the circulatory system
1.1 Vasculogenesis and angiogenesis
The need for oxygen and nutrients in a
body is supplied by the blood vessels.
The lymphatic vessels collect the
extravasated protein-rich tissue fluid,
filter it through the lymph nodes and
return it back to the circulation (Fig. 1).
The blood vasculature forms in a
coordinated manner through a
combination of vasculogenesis and
angiogenesis, and supports the growth
of the developing embryo. In the yolk
sac, the mesoderm-derived precursors,
hemangioblasts, form blood islands,
and give rise to both endothelial and
hematopoietic lineages (Fig. 2). In
vasculogenesis, the endothelial cells
(ECs) proliferate, differentiate and
assemble to form the early vascular
plexus (Carmeliet and Collen, 1999;
Flamme et al., 1997). In addition to the
extraembryonic formation of the
vasculature, hematopoiesis and
vasculogenesis also take place
intraembryonically, and the blood
vessels differentiating in the embryo
are connected to the yolk sac by
vitelline vessels.
After the development of the
primary vascular plexus, the mature
vasculature forms by sprouting and
remodeling from pre-existing vessels in
a process called angiogenesis
(Carmeliet, 2000; Risau, 1997). The
mature vasculature consists of a
complex organized network assembled
to arteries, capillaries, and veins.
Ephrins and their receptors are
involved in the patterning of blood
vessels from the earliest stages of
angiogenesis (Gale and Yancopoulos,
1999; Wang et al., 1998).
Figure 1. Circulatory system. A schematic drawing of the circulatory system indicating the
extravasation of fluid and macromolecules from the blood vessels, and their absorbtion into the
lymphatic vessels. (Modified from Jones et al., 2001; Karkkainen et al., 2001)
6Angiogenic sprout ing requires
programmed proteolytic activity to
selectively dissolve the extracellular
matr ix (ECM). The basement
membrane and ECM are degraded by
co-operation between adhesive and
proteolytic mechanisms (Reviewed in
Werb, 1997). For example the
plasminogen-plasmin system and
matrix metalloproteinases are involved
in the break-down of many ECM and
basement membrane proteins.
Migration of ECs is also facilitated by
integrins, which are ECM receptors
with distinct cellular and adhesive
specificities. Sprouting EC tubes fuse
and coalesce into loops, allowing blood
circulation in the newly vascularized
region.
Non-sprouting angiogenesis is a
process whereby pre-existing vessels
are split by transcapillary pillars of ECM
(Risau, 1997). In vivo this can occur
when ECs inside a vessel proliferate,
producing a wide lumen that can be
split by transcapillary pillars.
In the course of maturation, the
newly formed vessels are supported by
a basement membrane and a pericyte
layer and thus, become less vulnerable
to vessel regression (Benjamin et al.,
1998). The ECs themselves also
secrete growth factors, such as
platelet-derived growth factor (PDGF)-
B, which are important in the
recruitment of the supporting pericytes.
It has also been suggested that
circulating endothelial precursor cells
participate in angiogenesis in adults
(Shi et al., 1998). These cells are
immobilized after vascular trauma,
possibly due to the elevated circulating
levels of VEGF, further supporting the
idea that the endothelial precursors are
also involved in neo-angiogenesis (Gill
et al., 2001; Takahashi et al., 1999).
Recent findings also suggest that a
population of VEGFR-2 positive cells
may give rise to cells of both
endothelial and smooth muscle cell
(SMC) lineages (Yamashita et al.,
2000).
Figure 2. Differentiation of endothelial and hematopoietic cells. The endothelial and hematopoietic
cells are derived from a common precursor, the hemangioblast. The hemangioblasts aggregate and the
cells in the interior become hematopoietic cells, whereas the cells in the periphery differentiate into
primitive ECs, angioblasts. (Modified from Eichmann et al., 2000)
1.2 Growth factors and receptors involved in angiogenesis
1.2.1 Mechanisms of receptor
tyrosine kinase signaling
Targeted EC signaling is achieved by
specific receptor tyrosine kinases
(RTKs), which mediate growth factor
signals from the extracellular space to
the cytosol and finally to the nucleus of
the target cell. RTKs are classified into
subclasses based on sequence
similarities and distinct structural
characteristics (van der Geer et al.,
1994). However, the overall basic
structure of most RTKs is very similar.
They contain a l igand-binding
extracellular part, a single membrane
spanning region, and a cytosolic
domain for signal transduction. A
7juxtamembrane (JM) region preceding
the catalytic domain is located on the
cytoplasmic side, followed by the
conserved kinase domain that
catalyzes the transfer of the γ-
phosphate of ATP to tyrosine residues
of protein substrates.
C r y s t a l i z a t i o n  o f  t h e
unphosphorylated RTKs have revealed
molecular mechanisms by which RTKs
are kept in an unphosphorylated stage
(Reviewed in Hubbard et al., 1998).
The activation loop of the kinase seems
to be autoinhibitory in a monomeric
receptor ,  p revent ing  l igand-
independent phosphorylation. Recent
reports have also elucidated an
important role of the JM domain in
inhibition of RTK autophosphorylation
(Huse et al., 2001; Wybenga-Groot et
al., 2001).
Most known ligands for RTKs are
secreted soluble proteins. In the case
of VEGFs, the dimeric ligand binds to
the extracellular part of the receptor,
resulting in a symmetric receptor dimer
(Wiesmann et al., 1997). Dimerization
is followed by transphosphorylation of
the tyrosine recidues in the activation
loop, which stabilizes an active state of
the kinase via a conformation favorable
for catalysis (Hubbard et al., 1998;
Schlessinger, 2000).
Receptor phosphorylation generates
docking sites for downstream signaling
proteins. The phosphorylated tyrosine
residues and their adjacent sequences
act as specific activation sites for
downstream signal ing proteins
containing the Src homology 2 (SH2) or
phosphotyros ine-b inding (PTB)
domains. Further activation of multiple
s ignal  t ransduct ion cascades
eventually leads to biochemical
changes in the cell, such as
readjustment of gene expression.
1.2.2 VEGFs and their receptors
VEGF family members and their
receptors are critical regulators of both
angiogenesis and lymphangiogenesis
(Table 1) (Reviewed in Veikkola et al.,
2000). The importance of the parent
molecule VEGF in normal angiogenesis
has been implicated as inactivation of
even a single Vegf allele resulted in
lethality between E11-12 (Carmeliet et
al., 1996; Ferrara et al., 1996). The
Vegf+/- mice were growth retarded and
exhibited a number of developmental
anomalies. This phenotype appears to
be due to gene dosage and it is the first
case where the loss of a single allele is
lethal.
VEGF family members are secreted
glycoproteins that form either disulfide-
linked or non-covalently bound dimers,
whose subunits are arranged in an
antiparallel manner (Muller et al.,
1997). All the VEGF family members
contain a VEGF homology domain with
eight conserved cysteine residues.
Although VEGFs form structurally a
unified family, they differ in their
expression pat terns,  receptor
specificities and biological activities.
More diversity within the family is
obtained by alternative splicing. Splice
isoforms of VEGF, placenta growth
factor (PlGF), and VEGF-B differ in
their ability to bind heparin  and in their
tissue distribution. For example,
postnatal myocardial angiogenesis is
impaired in mice expressing only the
VEGF1 2 0 isoform, suggesting that
specific isoforms may be important for
an optimal angiogenic response in vivo
(Carmeliet et al., 1999). Biological
function of VEGFs is also affected by
heterodimerization and by proteolytic
processing (Cao et al., 1996; DiSalvo
et al., 1995; Joukov et al., 1997;
Olofsson et al., 1996; Stacker et al.,
1999).
8Table 1. VEGF family members
Growth factor Also known as Reference
VEGF vascular permeability factor, VPF (Senger et al., 1983)
(Ferrara and Henzel, 1989)
(Plouet et al., 1989)
PlGF (Maglione et al., 1991)
VEGF-B VEGF-related factor, VRF (Olofsson et al., 1996)
(Grimmond et al., 1996)
VEGF-C VEGF-related protein, VRP (Joukov et al., 1996)
(Lee et al., 1996)
VEGF-D c-fos-induced growth factor, FIGF (Orlandini et al., 1996)
(Yamada et al., 1997)
NZ2-VEGF
NZ7-VEGF
VEGF-Es, ORF-VEGFs
(viral VEGF homologues)
(Ogawa et al., 1998)
(Wise et al., 1999)
(Meyer et al., 1999)
To date, two receptor families,
VEGFRs and neuropilins (NRPs), have
been found to bind VEGFs. VEGFRs
are tyrosine kinase receptors, which
are expressed predominantly on the
surface of ECs. The three known
members of this family (VEGFR-1-3) all
contain seven extracellular Ig-
homology domains, of which the 2n d
and 3rd are necessary for ligand binding
and specificity (Fig. 3) (Davis-Smyth et
al., 1996; Fuh et al., 1998; Galland et
al., 1993; Matthews et al., 1991;
Mäkinen et al., 2001; Pajusola et al.,
1992; Shibuya et al., 1990; Terman et
al., 1991; Wiesmann et al., 1997). The
intracellular catalytic kinase domain of
VEGFRs is split by a kinase insert.
VEGFR-2 (KDR/Flk1) is a key
marker of hemangioblasts and
angioblasts, but its expression is
downregulated in hematopoietic cells.
The crucial role of VEGFR-2 for normal
vasculogenesis has been shown, as
Vegfr2-/- embryos fail to develop blood
islands and embryonic vasculature, and
die in utero between embryonic days
(E) 8.5-9.5 (Shalaby et al., 1995).
Furthermore, analysis of chimeric mice
showed that Vegfr2 is required cell
autonomously for both extraembryonic
and intraembryonic EC development
and hematopoiesis (Shalaby et al.,
1997). The interaction of VEGF with
VEGFR-2 seems to be a critical
requirement for the full spectrum of
VEGF induced biological responses.
Receptor selective VEGF mutants
which bind only to VEGFR-2 are fully
active EC mitogens, whereas the
mutants binding only to the VEGFR-1
have a substantially reduced ability to
promote EC growth (Keyt et al., 1996).
In addition, the virus-encoded ORF-
VEGFs bind to VEGFR-2 but not to
VEGFR-1, and they are capable in
inducing EC proliferation, migration and
permeability (Meyer et al., 1999;
Ogawa et al., 1998; Wise et al., 1999).
EC survival is also mediated via
VEGFR-2 (Gerber et al., 1998).
VEGFR-1 (Flt1) as a weak signaling
receptor, seems to act in concert with
VEGFR-2 to negatively regulate
physiological angiogenesis. In mouse
embryos, VEGFR-1 deficiency results
in increased proliferation of endothelial
precursors, whereas EC differentiation
is normal (Fong et al., 1995; Fong et
al., 1999). Surprisingly, mice lacking
the VEGFR-1 tyrosine kinase domain
appeared normal (Hiratsuka et al.,
1998).  O n l y  V E G F - i n d u c e d
macrophage migration was suppressed
in these mice, suggesting that VEGFR-
1 signaling is not required for
vasculogenesis, and that VEGFR-1
may play a role in inhibition of EC
proliferation. However, VEGFR-1 may
have an important role in pathological
angiogenesis. VEGFR-1 is upregulated
by hypoxia at the transcriptional level
(Gerber et al., 1997). In addition, It has
been shown that PlGF, which binds
only to VEGFR-1, is required for
pathological angiogenesis (Carmeliet et
al., 2001).
9Figure 3. Binding specificity of VEGF family members to the VEGFRs. (Achen et al., 1998; De
Vries et al., 1992; Joukov et al., 1996; Meyer et al., 1999; Ogawa et al., 1998; Olofsson et al., 1998;
Park et al., 1994; Terman et al., 1992; Wise et al., 1999)
VEGFR-1 ligands also act as
chemoattractants for cells of the
monocyte/macrophage lineage, which
express VEGFR-1 (Barleon et al.,
1996). VEGFR-1 signaling is required
for migration of these cells, and
inflammatory cells play an important
role in pathological angiogenesis and
collateral vessel growth (Hiratsuka et
al., 1998). Recently, it was also shown
that VEGF administration enhances the
formation of atherosclerotic plaques in
an experimental setting (Celletti et al.,
2001). This effect may occur via
monocyte/macrophage recruitment
from the bone marrow.
NRPs were characterized as
receptors for semaphorins, which have
a key role in mediating axonal guidance
during neuronal development (Chen et
al., 1997; He and Tessier-Lavigne,
1997; Kolodkin et al., 1997). However,
it was demonstrated that in addition to
normal neural development, NRP1 is
crusial for the formation of the
embryonic vasculature (Kawasaki et
al., 1999; Kitsukawa et al., 1995). In
contrast, mice with a targeted Nrp2
deletion are viable until adulthood
(Chen et al., 2000; Giger et al., 2000),
despite several problems in the
peripheral and central nervous
systems, indicative of a defective axon
guidance response.
NRPs have the ability to bind
various VEGFs in an isoform-specific
manner (Fig. 4) (Gluzman-Poltorak et
al., 2000; Migdal et al., 1998; Mäkinen
et al., 1999; Soker et al., 1998). It has
also been demonstrated that NRP-1
has a functional role in VEGF/VEGFR
signaling, as it enhances VEGF1 6 5
binding to VEGFR-2, and the VEGFR-2
mediated chemotactic response of ECs
(Soker et al., 1998). The extracellular
domain of NRP-1 also binds with high
affinity to immunoglobulin homology
domains 3 and 4 of VEGFR-1 (Fuh et
al., 2000). In addition, a naturally
occurring soluble form of NRP-1 binds
VEGF165 and shows antitumor activity
in an experimental rat prostate
carcinoma model, possibly by
antagonizing VEGF165 binding to its cell
surface receptors (Gagnon et al.,
2000).
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Figure 4. NRPs selectively bind members of the semaphorin and VEGF families. NRPs are
transmembrane proteins containing two CUB (complement-binding) domains (ovals), two coagulation
factor (V/VIII) domains (boxes), and a MAM (meprin, A5, µ) domain (arrow head) in the extracellular
part, a single transmembrane domain, and a short cytoplasmic tail.
It seems that the cytoplasmic tails of
NRPs do not possess signaling
capabilities but, instead, NRPs utilize
other receptors in signal transduction.
For example plexins, which themselves
do not bind secreted semaphorins,
form complexes with NRPs (Takahashi
et al., 1999; Tamagnone et al., 1999).
The plexin-1/NRP-1 complex has a
higher affinity to Sema3A than NRP-1
alone, and the intracellular signaling is
transmitted via this complex and
activation of a plexin-associated
tyrosine kinase. Thus, also in ECs
NRPs may signal by forming
complexes with VEGFRs.
In addition to the cell surface
receptors for VEGFs, naturally
occurring, soluble forms of VEGFR-1,
NRP-1, and NRP-2 have been found
(Gagnon et al., 2000; Kendall and
Thomas, 1993; Rossignol et al., 2000).
By inhibiting ligand binding to the
membrane receptors, these soluble
molecules may also act as naturally
occurring regulators of the angiogenic
processes. Whether addit ional
regulation is achieved by VEGFR
heterodimer formation, remains to be
seen.
1.2.3 Angiopoietins and Tie
receptors
Tie receptors (tyrosine kinase with Ig
and EGF homology domains) are
another family of EC specific RTKs. In
gene targeting studies, Tie1 and
Tie2/Tek (tunica interna endothelial cell
kinase) have been shown to have
distinct roles in vascular development
(Jones et al., 2001). The orphan
receptor Tie1 is needed for the
structural integrity of blood vascular
ECs, and its deficiency results in
oedema and localized hemorrhaging in
embryos (Puri et al., 1995; Sato et al.,
1995). Signaling via the Tek receptor is
particularly important in angiogenic
sprouting, vessel remodeling and
maturation (Dumont et al., 1994; Sato
et al., 1995).
Interestingly, Tek has two ligands
with dual actions, angiopoietin (Ang) 1
acts as an agonist for Tek, whereas
Ang2 usually functions as a naturally
occurring antagonist (Maisonpierre et
al., 1997; Teichert-Kuliszewska et al.,
2001). This is supported by the finding
that Tek promoter driven Ang2
overexpression in transgenic mice
results in a phenotype similar to that of
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mice deficient in Ang1 or Tek
(Maisonpierre et al., 1997; Suri et al.,
1996).
VEGF and angiopoietins act in a co-
operative and coordinated manner in
the formation and maintenance of
vessels. Whereas VEGF is thought to
promote EC proliferation, differentiation
and migration, angiopoietin signaling
via Tek mediates vessel maturation
and EC interaction with the supporting
cells. Recent data suggest that Ang1
can inhibit vascular permeability and
stabilize existing vessels. Transgenic
overexpression of Ang1 in mouse skin
results in enlarged vessels at normal
density due to circumferential growth,
whereas the dermal microvessels
induced by VEGF in the same model
were numerous, tortuous, and leaky
(Detmar et al., 1998; Suri et al., 1998).
Surprisingly, mice coexpressing both
Ang1 and VEGF in the skin showed
enlarged and more numerous, but
leakage-resistant vessels, suggesting
that Ang1 is capable of inhibiting the
VEGF induced permeability (Thurston
et al., 1999). Similar results were
obtained when adenoviral VEGF and/or
Ang1 were intravenously administered
to mice (Thurston et al., 2000).
In vessels undergoing active
remodeling, the stabilizing function of
Ang1 is overcome by an excess of
Ang2 expression. It has been
speculated that Ang2 is able to trigger
detachment of pericytes from the ECs,
which would then be more vulnerable
to an angiogenic stimulus, for example
VEGF (Gerber et al., 1999). Indeed,
Ang2 expression precedes that of
VEGF at sites of active vessel growth
in adults, for example during the
vascular remodeling in the ovary and in
tumors (Holash et al., 1999;
Maisonpierre et al., 1997; Stratmann et
al., 1998). Surprisingly, recent data
suggest that Ang2 has a role in
lymphatic development. The Ang2
knockout (KO) mice, exhibit chylous
ascites, with defects in the patterning
and function of the lymphatic
vasculature (G Thurston, C Suri, G
Yancopoulos, personal comm.).
1.2.4 Ephrins
During vascular network formation,
blood vessels assemble to form a
hierarchic pattern of arteries and veins,
connected by a capillary network.
Ephrins and their receptors are an
interesting ligand/receptor system,
which has a role in defining the
arterious/venous patterning of the
vessels, and in the EC/matrix
interactions. A special feature of this
system is that tyrosine kinase receptors
bind multimeric, membrane-bound
ligands, resulting in a bidirectional
signaling in the interacting cells
(Reviewed in Schmucker and Zipursky,
2001). It has been speculated that the
ephrin-B2/EphB4 signaling may provide
a repulsive effect in two adjacent cell
types, as ephrin-B2 and its receptor
EphB4 differentially mark the ECs of
arteries and veins, respectively (Wang
et al., 1998). It also seems that other
ephrins and Eph receptors are involved
in the development of the vasculature
(Reviewed in Gale and Yancopoulos,
1999).
Surprisingly, mice lacking ephrin-B2
or EphB4 resemble mice lacking either
Ang1 or Tek, with aberrant vessel
remodeling, sprouting and heart
trabeculation (Adams et al., 1999;
Gerety et al., 1999; Wang et al., 1998).
These results suggest that the
Ang1/Tek and ephrin-B2/EphB4
signaling pathways may interact.
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2 Lymphangiogenesis
2.1 Formation and function of the lymphatic system
The circulatory system, formed by the
heart and blood vessels, requires the
adjacent lymphatic system to collect
extravasated protein-rich fluid and
lymphocytes from the tissues, and
transport them back to the blood
circulation. These two systems
communicate with each other and are
in t imate ly  assoc ia ted dur ing
development.
The deve lopment  o f  the
cardiovascular system precedes the
development of the lymphatic system.
One theory postulates that the fetal
lymphatic sacs are formed from the
large central veins in the jugular and
perimesonephric regions (Sabin, 1912;
Sabin, 1902). The lymphatic vessels
then arise from these sacs by sprouting
towards the peripheral regions. Indeed,
the two lymphatic specific markers,
VEGFR-3 and Prox1, are expressed at
the sites for the suggested lymphatic
sacs during mouse development
(Dumont et al., 1998; Kaipainen et al.,
1995; Wigle and Oliver, 1999). All
lymphatic vessel links to the venous
system are disconnected, except for
the region of the left thoracic duct that
drains the lymph into the subclavian
vein.
In contrast to sprouting from pre-
existing veins, another theory suggests
that the lymphatic vessels develop by
in si tu  d i f f e ren t ia t i on  f rom
mesenchymal cells in different tissues
(Huntington and McClure, 1908;
Kampmeier, 1912), or by a combination
of sprouting and in situ formation (van
der Jagt, 1932). It has recently been
s h o w n  t h a t  m e s o d e r m a l
lymphangioblasts participate in the
development of the avian lymphatic
system, supporting the theory that the
peripheral lymphatic vessels develop
by multiple mechanisms (Schneider et
al., 1999; Wilting et al., 2000; Wilting et
a l . ,  2000).  Whe the r  these
lymphangioblasts also participate in
lymphangiogenesis in adults, remains
to be seen.
The lymphatic vessels collect the
interstitial fluid and transport it back to
the blood. Fluid and macromolecules
from the stromal compartment enter the
initial lymphatic sinuses and lymphatic
capillaries, which consist of a single,
flat EC layer surrounded by an
incomplete basement membrane. The
ECs of the lymphatic capillaries also
have large inter-endothelial gaps,
which facilitate the trafficking of
macromolecules. From the capillaries,
the fluid is transferred to the collecting
lymphatic vessels, and ultimately into
the venous circulation via the thoracic
duct. Larger lymphatic vessels are
surrounded by a muscular layer that
contracts automatically when the
lymphatic vessel becomes stretched
with fluid. In addition, external factors
such as skeletal muscle movements
and arterial pulsation compress the
lymphatic vessels and increase the
efficiency of fluid transfer (Guyton,
1991). The LECs are attached to the
surrounding connective tissue by
anchoring filaments. Furthermore, the
luminal side the lymphatic vessels is
segmented by valves, which prevent
lymphatic back-flow.
In addition to fluid transport, the
lymphatic system also has an important
role in immunological responses.
Lymphatic vessels take up any foreign
molecules and leukocytes which have
gained access to the tissue spaces.
The lymph is filtered through the lymph
nodes, which trap various antigens and
attract antigen presenting cells, such as
dendritic cells (DCs) in various epithelia
or Langerhans cells in the epidermis.
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These cells monitor the extracellular
environment, detect antigens, and
trigger T cell activation (Rescigno and
Borrow,  2001).  In f lammatory
chemokines recruit DC precursors and
mediate DC activation. The DCs then
migrate from the periphery to the lymph
nodes via the lymphatic vessels.
Activated DCs upregulate the cytokine
receptor CCR7 and become sensitive
to its ligands SLC (secondary lymphoid
tissue chemokine) and ELC (Ebstein-
Barr virus-induced ligand for CCR7),
which are expressed for example in the
high endothelial venules, and in the T
cell rich areas of lymph nodes,
respectively (Cyster, 1999). Also other
specific chemokines and chemokine
receptors are involved in cell trafficking
in the lymphatic system. For example
the β-chemokine receptor D6 is
expressed in the skin and intestinal
lymphatic vessels and in the lymph
nodes, suggesting that this receptor
may have a role in cell trafficking in
these organs (Nibbs et al., 2001).
As metastasis to the regional lymph
nodes occurs via the lymphatic vessels,
recent areas of interest regarding the
LECs are their interactions with tumor
cells, the transfer of cells through the
endothelium and their entry into the
lymph nodes. Knowledge of the
mechanisms regulating cell trafficking
into the lymphatic vessels and into the
lymph nodes could be helpful in trials to
prevent the metastatic process.
2.2 VEGFR-3 and its ligands in lymphangiogenesis
The first characterized marker for the
lymphatic endothelium was VEGFR-3
(fms -like tyrosine kinase 4, FLT4)
(Galland et al., 1993; Pajusola et al.,
1992). During embryogenesis, VEGFR-
3 is first expressed in a subset of blood
vascular ECs (Kaipainen et al., 1995).
Accordingly, mice deficient in the
Vegfr3 gene show abnormal
remodeling of the primary vascular
plexus and die at E9.5 (Dumont et al.,
1998). However, during further
development Vegf r3 expression
becomes mainly restricted to the
lymphatic vessels (Dumont et al., 1998;
Kaipainen et al., 1995), and several
studies have indicated the importance
of VEGFR-3 as a mediator of
lymphangiogenesis.
In humans, but not in mice, the
V E G F R 3  gene encodes two
polypeptides that differ at their C-
terminus due to alternative splicing
(Galland et al., 1993; Pajusola et al.,
1993). The protein corresponding the
longer transcript is more abundant, and
its C-terminus contains three tyrosyl
residues, of which Y1337 is important
in signaling (Fournier et al., 1995).
VEGF-C and VEGF-D bind to and
activate VEGFR-3 (Achen et al., 1998;
Joukov et al., 1996; Lee et al., 1996;
Orlandini et al., 1996; Yamada et al.,
1997). During development, the
distribution of the VEGFR-3 mRNA
follows a somewhat similar spatio-
temporal  pattern to VEGF-C
expression, suggesting paracrine
ligand-receptor signaling (Kukk et al.,
1996). Knocking out these genes
should reveal their importance during
development. Although VEGF-C and
VEGF–D show different expression
patterns during embryogenesis, it is
possible that they compensate for each
other at sites of overlapping
expression, such as in the lung and in
the kidney mesenchyme (Avantaggiato
et al., 1998; Kukk et al., 1996).
Both VEGF-C and VEGF-D are
lymphangiogenic. VEGF-C is mitogenic
towards LECs and shows a selective
lymphangiogenic response in
differentiated avian chorioallantoic
membrane (Oh et al., 1997).
Accordingly, overexpression of VEGF-
C in transgenic mice induces the
development of a hyperplastic
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lymphatic vessel network (Jeltsch et al.,
1997; Mandriota et al., 2001). Recent
data also suggest that VEGF-D, and a
VEGFR-3 specific mutant of VEGF-C
(VEGF-C156S) are lymphangiogenic
when overexpressed in the skin of
transgenic mice (Joukov et al., 1998;
Veikkola et al., 2001). Conversely,
inhibition of lymphatic growth is
obtained when a soluble form of
VEGFR-3 is expressed in a similar
transgenic mouse model (Mäkinen et
al., 2001). These results and the
expression patterns of VEGF-C and
VEGFR-3 in the lymphatic vasculature
suggest that lymphatic growth is
induced by VEGF-C and mediated via
VEGFR-3.
As VEGF-C and VEGF-D bind both
VEGFR-2 and VEGFR-3, they are
capable of activating these receptors
on the lymphatic endothelium and
VEGFR-2 on blood ECs. Proteolytic
cleavage is an important regulator of
the receptor binding and thus, the
biological activity of VEGF-C and
VEGF-D. Unlike the other VEGFs,
VEGF-C and VEGF-D have N- and C-
terminal extensions, and are
proteolytically cleaved upon secretion
(Fig. 5) (Joukov et al., 1997; Stacker et
al., 1999). Receptor binding affinity is
enhanced during the stepwise
processing of VEGF-C and VEGF-D,
and only the fully processed forms of
these growth factors bind to VEGFR-2.
Binding to VEGFR-2 on blood vessels
may explain the angiogenic potential of
VEGF-C and VEGF-D under certain
conditions (Cao et al., 1998; Marconcini
et al., 1999). The ability of VEGF-C to
induce blood vessel permeability is also
mediated via VEGFR-2 (Joukov et al.,
1998). Interestingly, mouse VEGF-D
does not bind mouse VEGFR-2,
suggesting that the biological functions
of VEGF-D differ in mouse and man,
and that VEGF-D interaction with
VEGFR-2 is not crucial for normal
development (Baldwin et al., 2001).
It has been suggested that VEGF-C
and VEGF-D are involved in tumor
angiogenesis and lymphangiogenesis,
because their  expression is
upregulated in certain metastatic
human tumors (Achen et al., 2001;
Yonemura et al., 1999). In addition,
VEGF-C and VEGF-D may also induce
tumor angiogenesis via VEGFR-3,
which is upregulated in angiogenic
blood vessels in tumors (Valtola et al.,
1999). Several experimental models
suggest that overexpression of these
growth factors can increase the
metastatic rate of tumors. Double
transgenic mice having both VEGF-C
and SV40 virus large T-antigen
overexpression in pancreatic β-cells,
showed increased metastasis via the
lymphatic vessels (Mandriota et al.,
2001). VEGF-C overexpression in
tumor xenografts implanted onto
immunocompromised mice also
r e s u l t e d  i n  i n c r e a s e d
lymphangiogenesis and metastasis
formation (Karpanen et al., 2001;
Skobe et al., 2001a), whereas two
other VEGF-C overexpressing tumor
models suggested that VEGF-C also
induces angiogenesis (Kadambi et al.,
2001; Skobe et al., 2001b). VEGF-D
overexpression in a tumor xenograft
model resulted in both angiogenic and
lymphangiogenic responses (Stacker et
al., 2001). Thus, the lymphangiogenic/
angiogenic properties of VEGF-C and
VEGF-D may depend on the tissue
setting, or on protease expression and
processing of the growth factors in
these models. For example, only
lymphangiogenesis was enhanced
when very little of VEGF-C was present
in the fully processed form (Skobe et
al., 2001a). Inhibitors of the
lymphangiogenic factors could serve as
potential therapeutic tools to inhibit
tumor metastasis. Indeed, in the
experimental models, both soluble
receptors and blocking antibodies have
been shown to inhibit metastasis via
the lymphatic vessels (Karpanen et al.,
2001; Stacker et al., 2001).
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Figure 5. The proteolytic processing of VEGF-C and VEGF-D. The first cleavage site is marked with
an open arrowhead, and the second by a black arrowhead. Numbers indicate the approximate
molecular masses (kD) of the corresponding polypeptides in reducing conditions. The regions of the
VEGF-C polypeptide are marked as follows: VHD; VEGF homology domain, N-term; N-terminal
propeptide, C-term; C-terminal propeptide, ss; disulphide bonds. (Modified from Joukov et al., 1997;
Stacker et al., 1999)
In addition to the importance of VEGF-
C in tumor lymphangiogenesis, it has
been shown that VEGFR-3 is also
present in fenestrated capillaries or
veins of several organs including the
bone marrow, splenic and hepatic
sinusoids, kidney glomeruli and certain
endocrine glands (Partanen et al.,
2000). VEGF-C was detected in
neuroendocrine cells such as the α
cells of the islets of Langerhans,
prolactin secreting cells of the anterior
pituitary, adrenal medullary cells, and
dispersed neuroendocrine cells of the
gastrointestinal tract. These results
suggest that VEGF-C functions in a
paracrine manner, and that the VEGF-
C/VEGFR-3 signaling may have a role
in peptide release from secretory
granules of certain neuroendocrine
cells to surrounding capillaries.
2.3 Other lymphatic endothelial specific factors
2.3.1 Prospero-related homeobox
protein 1 (Prox1)
In addition to VEGFR-3, there are
some other genes which are largely
expressed in LECs. The expression
pattern of the homeobox gene Prox1
suggested that it has a functional role
in the developing central nervous
system (Oliver et al., 1993). However,
results with Prox1-/- mice showed that
in addition to the liver and lens-fibre
development, Prox1 is essential in the
formation of the lymphatic vasculature
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(Sosa-Pineda et al., 2000; Wigle et al.,
1999; Wigle and Oliver, 1999).
The marker gene expression in the
Prox1  targeted mice showed that
starting as early as E9.5, Prox1 is
expressed in the subpopulation of EC,
in the regions that give rise to the
lymphatic sacs. In the Prox1 deficient
mice, the budding and sprouting of the
lymphatic endothelial cells from these
regions were arrested, suggesting that
some unidentified guidance signals
may regulate the migration of the Prox1
expressing LECs (Wigle and Oliver,
1999).
Dur ing embryogenesis,  the
expression pattern of Prox1 in the
develop ing lymphat ic  system
resembles that of VEGFR-3 (Dumont et
al., 1998; Wigle and Oliver, 1999).
Interestingly, Prox1 haplo-insufficiency
in Prox1+/- newborn mice leads to
chylous fluid accumulation into the
intestine, and death a few days after
birth (Wigle and Oliver, 1999). These
results suggest that Prox1 is required
for lymphatic, but not blood vessel
development and that even haplo-
insufficiency of Prox1 results in
improper development of the enteric
lymphatic vessels.
2.3.2 Podoplanin
Podoplanin is an integral plasma
membrane protein first found in
glomerular epithelial cells, where it
controls the shape of podocytes
(Breiteneder-Geleff et al., 1997; Matsui
et al., 1999). In addition to podocytes,
podoplanin is also expressed in the
endothelium of lymphatic capillaries,
but not in the blood vasculature
(Breiteneder-Geleff et al., 1999;
Kriehuber et al., 2001; Mäkinen et al.,
2001). In the skin and kidney,
podoplanin co-localizes with VEGFR-3,
and the ECs of Kaposi's sarcomas
express both VEGFR-3 and
podoplanin, which supports their
suggested lymphatic endothelial origin
(Breiteneder-Geleff et al., 1999;
Weninger et al., 1999). However, the
function of podoplanin in LECs is not
known.
2.3.3 Lymphatic vessel endothelial
hyaluronan receptor 1 (LYVE-1)
The ECM glycosaminoglycan
hyaluronan (HA) plays an important
role in the maintenance of tissue
integrity and facilitation of cell migration
during embryogenesis, wound healing
and inflammation. HA is rapidly
degraded within lymph nodes. The
integral membrane protein LYVE-1 has
been identified as a new LEC specific
receptor for HA (Banerji et al., 1999). It
is distributed equally on the luminal and
abluminal surfaces of lymphatic
vessels, and it transports HA across
the lymphatic endothelium into the
lymph (Prevo et al., 2001). LYVE-1 is
homologous to CD44, which is required
for lymphocyte entry into the adult
thymus (Banerji et al., 1999; Protin et
al., 1999). Extravasation of CD44
expressing lymphocytes is mediated by
their interaction with HA-coated
vascular endothelium in inflammation
and increased amounts of HA in the
tumor interstitium predict poor survival
of the patients (Auvinen et al., 2000;
DeGrendele et al., 1997). It remains to
be seen whether LYVE-1 plays a role in
metastasis via the lymphatic vessels,
for example by assisting the
intravasation of HA expressing tumor
cells.
The specific roles of Prox-1,
podoplanin and LYVE-1 functions in the
LECs remain to be studied. However,
these markers can now be utilized to
study lymphatic development and to
explore the etiology of diseases, in
which the lymphatic vessels are
affected.
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3 Diseases associated with RTK dysfunction
3.1 Lymphedema
3.1.1 Pathophysiology of
lymphedema
Lymphatic vessels play a central role in
maintaining the fluid balance of the
interstitial tissues. If this balance is
disturbed, for exapmple if the amount
of lymphatic fluid formed exceeds the
lymphatic absorption or transport
capacity, a protein-rich fluid collects in
the interstitium. Lymphedema is
characterized by a chronic, disfiguring
and disabling swelling of one or several
limbs due to insufficient lymphatic
drainage, but not due to increased
vascular permeability (Reviewed in
Rockson, 2001).
Isotopic lymphoscintigraphy and
magnetic resonance imaging (MRI)
have been used to visualize the edema
and functional defects of the lymphatic
system in lymphedema patients. In
lymphoscintigraphy, a radiolabeled
macromolecular tracer is administered
into the subcutaneous tissue of the
affected limb, and the major lymphatic
trunks and lymph nodes are visualized.
In the lymphedematous area, the
transport of the tracer is absent or
delayed, and dermal backflow
(progressive dispersion of the tracer
into the soft tissues) can be detected.
MRI analysis reveals structural
changes such as thickening of the skin
with diffuse dermal and subcutaneous
edema, an intact  subfascia l
compartment and variability in regional
lymph node size (Case et al., 1992;
Idy-Peretti et al., 1998). These changes
are not necessarily distinguishable
between primary and secondary
lymphedema (Idy-Peretti et al., 1998).
3.1.2 Classification of lymphedema
Lymphedema is divided into two main
categories. Primary lymphedema is a
condition with no identifiable cause,
whereas secondary lymphedema
results from a disruption of the
lymphatic circulation due to an earlier
d isease or  t rauma. Pr imary
lymphedema can be present at birth, or
develop at puberty or, more rarely, in
adulthood (Witte et al., 1997). In
congenital hereditary lymphedema
(Milroy’s disease) the superficial
lymphatic vessels are usually
hypoplastic or aplastic. In contrast, the
microlymphatic network in late onset
lymphedema (Meige’s disease) usually
appears larger than in healthy controls
(Bollinger, 1993; Bollinger et al., 1983;
Pfister et al., 1990). Approximately 35%
of primary lymphedema patients have a
positive family history of the disease
(Dale, 1985). It has been estimated that
approximately 1:6000 newborns will
even tua l l y  deve lop  p r imary
lymphedema, with sex ratio of one
male to three females (Dale, 1985).
In contrast to primary lymphedema,
secondary or acquired lymphedema
develops when the lymphatic vessels
are damaged by infection, radiation
therapy or when lymph nodes are
surgically removed. It has been
estimated that 3-5 million people in
USA have secondary lymphedema.
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Figure 6. Lymphatic filariasis. Filariasis is caused by Wuchereria bancrofti microfilarial worm infection
(left). The filarial infection in some cases results in massive swelling of the leg (right). Images:
WHO/TDR Image Library, photographers: Stammers and Dreyer
The most common form of
lymphedema results from filariasis (Fig.
6). According to the World Health
Organization (WHO), over 120 million
people suffer from filarial lymphedema
worldwide, mainly in tropical and
subtropical areas. In addition to
enlargement of the entire leg, arm, or
genitals, filariasis may also cause
internal damage to the kidneys and the
lymphatic system. Lymphatic filariasis
is caused by the parasitic filarial worms
Wuchereria bancrofti and B r u g i a
malayi . These worms lodge in the
lymphatic system, where they live for 4-
6 years, producing millions of immature
microfilariae (minute larvae) that
circulate in the blood. The disease is
further transmitted by mosquitoes that
bite infected humans and pick up the
microfilariae, which then develop inside
the mosquito and are transmitted to
other humans. The infection is
generally acquired during childhood,
but the development of lymphedema
takes several years.
In all forms of lymphedema, the
persistent accumulation of stagnant,
protein-rich fluid into the interstitium
reduces oxygen availability in tissues
and the normal immune defences are
partially lost. As a consequence, the
affected area often shows increased
t issue f ibros is  and adipose
degeneration, interference with wound
healing, and susceptibility to infections.
3.1.3 Genetic alterations in
lymphedema
Despite having been described over a
century ago, little progress has been
made in understanding the molecular
mechanisms causing hereditary
lymphedema. Recently, several groups
reported linkage of the early onset
primary lymphedema to the VEGFR3
region on distal chromosome 5q
(Aprelikova et al., 1992; Evans et al.,
1999; Ferrell et al., 1998; Galland et al.,
1992; Witte et al., 1998), and five
specific lymphedema-linked missense
mutations were found in the VEGFR-3
tyrosine kinase domain (Irrthum et al.,
2000; Karkkainen et al., 2000).
While mutations which inhibit the
biological activity of VEGFR-3 are one
cause of primary lymphedema, there
are several lymphedema families and
other lymphedema syndromes which
invo lve  o ther  genet ic  loc i .
Lymphedema-d is t i ch ias is  (LD)
syndrome has been linked to
chromosomal region 16q24 (Bell et al.,
2000; Mangion et al., 1999). LD is
characterized by pubertal lymphedema
with enlarged cutaneous lymphatic
vessels, and a double row of
eyelashes. In addition, 16% of the LD
patients also show congenital heart
disease (Corbett et al., 1982).
Mutations in the FOXC2 (MFH1) gene
has been identified in the LD patients
(Fang et al., 2000).
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Figure 7. FOXC2 mutations in the lymphedema distichiasis families. A schematic structure of the
FOXC2 protein is presented. All mutations marked with a circle result in a truncated protein with or
without a novel C-terminus. The one missense mutation discovered (C374T; S125L) is indicated by an
arrow.
FOXC2 encodes a member of the
forkhead/winged-helix family of
transcription factors, which are involved
in diverse developmental pathways
(Miura et al., 1993). Foxc2-/- mice die
during embryogenesis or perinatally,
and exhibit cardiovascular defects,
such as interrupted aortic arch, and
skeletal defects, such as cleft palate
(Iida et al., 1997; Winnier et al., 1997).
However, Foxc2+/- mice do not have an
obvious phenotype, and they show only
mild defects in ocular development
(Smith et al., 2000). So far, no
lymphedema has been detected in
mice deficient in Foxc2. Results from
KO mouse studies are thus in
disagreement somewhat with the
severe phenotype caused by the
heterozygous FOXC2 mutations in the
human LD patients.
Small insertions or deletions have
been found throughout the FOXC2
gene in LD patients, often resulting in a
premature termination of the FOXC2
protein and production of a novel C-
terminus (Fig. 7) (Bell et al., 2001;
Finegold et al., 2001). Thus, FOXC2
haplo-insufficiency appears to be one
cause of LD. The broad phenotypic
heterogeneity within the families
suggests that FOXC2 mutations may
be the cause of lymphedema in families
displaying phenotypes attributed to
other lymphedema syndromes
(Finegold et al., 2001). Interestingly,
FOXC2 expression also counteracts
obesity, hypertriglyceridemia, and diet-
induced insulin resistance (Cederberg
et al., 2001), This result may provide
connection to the adipose tissue
accumulation which is often associated
with lymphedema.
Mutations within V E G F R 3  and
FOXC2 are the only ones which have
been found to cause hereditary
lymphedema. In addit ion, two
chromosomal regions have been linked
to other lymphedema syndromes
(Table 2). The disease locus in
cholestasis-lymphedema syndrome,
characterized by severe neonatal
cholestasis and chronic severe
lymphedema, was mapped to
chromosome 15q (Bull et al., 2000).
One of the variable features of Turner
syndrome (complete or part absence of
one of the X chromosomes) is
lymphedema. The locus responsible for
the symptoms of this disease has been
mapped to a region Xp11.2-p22.1 (Zinn
et al., 1998). Interestingly, the VEGFD
(FIGF) gene is also located in Xp22.1
(Rocchigiani et al., 1998), but there are
no reports of involvement of VEGF-D in
Turner syndrome.
Table 2. Genetic alterations in lymphedema syndromes
Lymphedema syndrome MIM* Age at onset Gene loci Gene
Milroy’s disease 153100 congenital 5q34-q35 VEGFR3
Lymphedema-distichiasis (LD)
syndrome
153400 puberty 16q24.3 FOXC2
cholestasis-lymphedema
syndrome
214900 puberty 15q Not known
Turner syndrome - congenital Xp11.2-p22.1 Not known
* Mendelian inheritance in man (http://www3.ncbi.nlm.nih.gov/Omim/)
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All these reports suggest that other
lymphedema genes exist. Further
studies may reveal new factors
affecting LEC regulation and help us to
explain the genotypic and phenotypic
heterogeneity of lymphedema. It should
also be noted that not all members of
primary lymphedema families with
inactivating VEGFR3  mutations are
affected by the disease (Karkkainen et
al., 2000). This suggests that additional
genetic or environmental factors play a
role in the development of
lymphedema.
3.2 Inactivating RTK mutations in human syndromes
Among the 20 different RTK families,
several inherited mutations have been
found to be involved in the
development of human diseases. Many
of these occur near the transmembrane
domain and lead to constitutive
activation of the tyrosine kinase
(Reviewed in Robertson et al., 2000).
This uncontrolled activity often leads to
familial predisposition to develop
neoplasia. Inheri ted neoplasia
syndromes can result from activating
MET (hepatocyte growth factor
receptor) mutations in multiple papillary
renal cell carcinomas and RET
(rearranged during transformation)
mutations in multiple endocrine
neoplasia (MEN). Alternatively,
activating mutations may also result in
developmental abnormalities, such as
fibroblast growth factor receptor
(FGFR)-3 mutations in dwarfism and
mutations in other FGFRs in
craniosynostosis syndromes. In the
RTKs expressed on ECs, activating
TEK mutations have been found in
venous malformations (Vikkula et al.,
1996). A single point mutation (R859W)
within the Tek kinase domain leads to
an increase of RTK activity. Lesions
result due to large venous channels
with a low number of surrounding
smooth muscle cells.
In contrast to many activating
mutations in RTKs, their inactivating
mutations in inherited conditions are
rare. This may be due to the fact that
signaling via RTKs is essential during
normal development, and inactivating
mutations are likely to act in a dominant
negative manner, thus quenching
downstream signaling. The KIT
receptor provided the first example of a
loss-of-function mutation in an inherited
disease both in humans and in mice
(Giebel and Spritz, 1991; Tan et al.,
1990). KIT is a member of PDGFR
family and binds stem cell factor (KIT
ligand, KL). Loss-of-function mutations
within the KIT receptor have been
found in piebaldism, characterized by a
lack of pigmentation leading to white
patches of skin and hair due to
defective melanocyte migration. Milder
forms of piebaldism are caused by
mutations which lead to disruption of
the extracellular domain and thus an
inability to respond to the ligand. More
severe disease is caused by
inactivating missense mutations in the
tyrosine kinase domain due to a
dominant negative effect (See
references in Robertson et al., 2000).
Activating mutations within KIT have
been ident i f ied in  inher i ted
gastrointestinal stromal tumors (GIST).
Interestingly, a (KIT, ABL, and
PDGFRβ) specific tyrosine kinase
inhibitor, STI571, has been found to be
an excellent therapeutic agent for GIST
(Joensuu et al., 2001; Tuveson et al.,
2001).
Inactivating mutations have also
been found in RET, which is required
for the normal development of the
kidney, enteric system, and neural
crest. RET binds the ligands of the
glial-derived neurothrophic factor
(GDNF) family in a heterodimeric
complex with glycosylphosphatidyl-
inositol-linked receptors (GFR-α-1-4).
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Deletions or point mutations within RET
have been assoc ia ted wi th
Hirschsprung disease, which is
characterized by absence of enteric
ganglia along the gastro-intestinal tract
and leads to bowel obstruction in
neonates (Reviewed in Eng and
Mulligan, 1997). The mutations in
Hirschsprung disease are predicted to
encode truncated, inactive or non-
expressed RET receptors, and act in a
dominant negative manner. In addition
to these inactivating mutations, gain-of-
function mutations of RET have been
identi f ied in inheri ted cancer
syndromes, such as in MEN and in
familial medullary thyroid carcinoma
(Jhiang, 2000). Surprisingly, in some
families a single point mutation results
in both Hirschsprung disease and
MEN, suggesting that different cells
may require different balancing of RTK
signaling (Takahashi et al., 1999).
4 Gene therapy
4.1 Vectors and approaches
Gene therapy aims to transfer genes
into cells to correct genetic defects, or
to express other therapeutic gene
products (Lemoine, 1999).  For
treatment of monogenic diseases, the
expression of the defective gene may
be introduced into the cells involved in
the pathology, or into their precursors
either by ex vivo, in situ, or in vivo gene
transfer. So far, only somatic gene
therapy has been applied to human
patients. Germline gene therapy cannot
be attempted until more studies and
safety trials have been performed, and
until the mechanisms affecting the
successful gene therapy are fully
understood. The ethical issues also
need to be carefully considered before
studies of  germl ine genet ic
engineering.
All gene therapeutic strategies
depend on the delivery of genetic
material into the cell and thence the
nucleus. Methods currently involve
gene transfer using viruses, naked
DNA, or DNA-cationic liposome
complexes. Although naked DNA or
cationic liposomes are non-toxic and
non-immunogenic, they are relatively
inefficient. Thus, viral gene therapies
are of most interest if high expression
levels and long-term therapies are
required. Several viruses, such as
adenoviruses, adeno-associated
viruses (AAVs), retroviruses, and
Herpes simplex viruses have been
used as vectors to introduce genes into
the cells. The viral genomes are
modified to delete the regions which
are important in viral replication, thus
limiting the process to only a single
infectious cycle and increasing the
safety of the therapy.
Adenoviruses are commonly used
for gene transfer. These viruses infect
several cell types, and have been used
to give high-level, but short-term gene
expression in several tissues, such as
the lung, liver, and muscle (Kresina,
2001). Adenoviruses have a natural
tropism for epithelial cells, and can
infect non-dividing cells. Most of the
a d e n o v i r u s e s  u t i l i z e  t h e
coxackie/adenovirus receptor (CAR) for
cell attachment, and the exposed RGD
motif in the viral capsid is important in
integrin-mediated virus entry into the
cell (Roelvink et al., 1999; Stewart et
al., 1997; Tomko et al., 1997; Wickham
et al., 1993). When administrated
intravenously, the adenoviruses mostly
infect the liver. WT adenoviral
infections are associated with very
minor symptoms, such as acute
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respiratory infections. However, the
consequences may be severe in
immunosuppressed patients. Although
adenoviruses give a high-level of gene
expression, their major limitation is that
transgene expression is lost within a
month, which is partly due to an
immune response to the remaining viral
proteins.
Whereas the adenoviral gene
transfer only gives short term
expression, AAVs may give transgene
expression for a year (Daly et al.,
2001). AAVs are non-pathogenic
human viruses, which do not elicit an
inflammatory reaction or a cytotoxic
immune response, and infect both the
dividing and non-dividing cells of
several organs (Reviewed in Monahan
and Samulski, 2000). AAVs are
replication deficient and require a
helper virus (usually adenovirus or
herpesvirus). Viral entry into the cells is
mediated by cell surface receptors
such as heparan sulfates, α vβ5
integrins, and FGFR-1 (Qing et al.,
1999; Summerford et al., 1999;
Summerford and Samulski, 1998). One
disadvantage in the use of AAVs is
their limited packaging capacity, as
they cannot accommodate more than
4.5 kb of foreign DNA. Whereas WT
AAVs integrate site-specifically to
chromosome 19 (Kotin et al., 1990),
recombinant viruses may integrate
randomly into the host genome, and
put the patients at risk of insertional
mutagenesis. Despite this, AAV
encoded Factor IX has been used to
treat haemophilia B and CTFR (Cystic
fibrosis transmembrane regulator) to
treat cystic fibrosis (Kay et al., 2000;
Wagner et al., 1999). These studies
demonstrate that there is no vector-
related toxicity, germline transmission,
or formation of inhibitory antibodies. It
was also shown that AAV gives long-
term expression in humans.
For diseases caused by dominant
negative mutations, very few gene
therapeutic trials have been attempted.
Overexpression of the WT protein, or
inhibition of mutant protein expression
are the two main strategies which have
been attempted in trials to decrease a
dominant negative effect. Antisense
techniques are a way to decrease the
amount of a mutant protein product.
This has been tried in vitro with
osteogenesis imperfecta, which results
from a mutation in the proα chains of
type I collagen (Niyibizi et al., 2000). In
this technique the specific antisense
DNA oliconucleotides bind the target
mRNA, and the complex is digested by
intracellular enzymes. A more specific
cleavage of the target mRNA has been
investigated using ribozymes, which
also provide a way to target point
mutations. (Lewin and Hauswirth,
2001). In Marfan syndrome, which
results from dominant negative
mutations in fibrillin-1, ribozymes have
been shown to be efficient at cleavage
of f ibri l l in RNA (Kilpatrick and
Phylactou, 1998). So far, diseases
caused by inactivating dominant
negative RTK mutations have not been
treated with gene therapy.
4.2 Gene therapy in ECs
Angiogenesis is a novel target for gene
therapy (Reviewed in Ferrara and
Alitalo, 1999). In attempts to
manipulate angiogenesis, VEGFR-2 i s
of the highest interest therapeutically
because it dominates the angiogenic
response to VEGF. Depending on the
disease concept ,  therapeut ic
angiogenesis may aim at induction of
new vessel growth or inhibition of
angiogenesis. Pro-angiogenic therapy
has been shown to be efficient in
ischemia models, such as in hindlimb
ischemia and in myocardial infarction
(Harada et al., 1994; Laitinen et al.,
1998; Pearlman et al., 1995; Pu et al.,
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1993; Takeshita et al., 1994). In
addition, angiogenic factors have been
found to be beneficial in the prevention
of arterial restenosis after balloon
angioplasty (Asahara et al., 1995). One
benefit of the treatments applied so far
is that they require only a short-term
and local expression of the therapeutic
gene.
Adenov i ra l  (Ad )  VEGF-C
overexpression has been shown to
induce lymphangiogenesis in the ears
of nude mice (Enholm et al., 2001). The
VEGF-C receptors VEGFR-2 and
VEGFR-3 were upregulated in ECs
after AdVEGF-C infection, but there
was no effect on angiogenesis. In
addition, VEGF-C gene transfer has
been studied both in a restenosis
model and in ischemic hind limb model.
It was shown that AdVEGF-C
expression is able to reduce intimal
thickening after balloon injury in a
rabbit model (Hiltunen et al., 2000). In
the rabbit ischemic hindlimb model,
VEGF-C was shown to promote
collateral formation (Witzenbichler et
al., 1998), suggesting that VEGF-C
may be angiogenic in vivo under
certain conditions. One explanation for
these results may be that the mature
form by binding to VEGFR-2, may
directly induce angiogenesis. The
proteases involved in VEGF-C
processing are not known. If some of
the proteases are upregulated by
hypoxia and cytokines, more of the
mature VEGF-C, capable of binding
VEGFR-2 would then be produced. On
the other hand, VEGF levels are
strongly upregulated in hypoxic
conditions, and it has been shown that
VEGF and VEGF-C synergize in their
in vitro angiogenic response (Pepper et
al., 1998). Thus, it is possible that
VEGF-C acts in concert with VEGF
under these conditions, or that the
angiogenic properties of VEGF-C may
be indirect via a synergistic effect with
VEGF and/or  v ia  VEGFR-2
upregulation.
As a conclusion, detailed studies of
the factors involved in EC growth and
regulation could allow us to manipulate
the various steps in angiogenesis and
lymphangiogenesis. In the future,
therapeutic approaches may include
targeting of therapeutic gene
expression to the desired ECs, for
example into the tumor endothelium.
This goal may be achieved by targeting
viral entry to the desired cells only. This
approach is facilitated by the finding
that the ECs are heterogenic and thus,
distinct targeting molecules can be
used (Ruoslahti and Rajotte, 2000).
Alternatively, the promoters of the
TIE1, TEK, KDR, ICAM1, or endoglin
genes could be used to achieve EC
specific expression of the therapeutic
gene. The lymphatic endothelial cell
specific promoters could also be used
to target lymphatic endothelium.
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AIMS OF THIS STUDY
This study was undertaken to analyse the role of VEGFR-3 in inherited
lymphedema. A further aim was to characterize a mouse model and treatment
possibilities for primary lymphedema.
In order to explore these questions, I have studied:
1. The structure and polymorphisms of the VEGFR3 gene
2. Functional abnormalities of lymphedema-linked mutant VEGFR-3s
3. Phenotypic features of the Chy mouse model for human primary lymphedema
4. Effects of growth factor therapy on Chy mice
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MATERIALS AND METHODS
A brief summary of the methods used will be given here. Methods are described
and discussed in more detail in the original publications.
1 The VEGFR3 genomic structure and regulatory region (I)
We characterized the VEGFR3 gene
and its regulatory 5' flanking region
using a genomic cosmid clone
containing these sequences. The exon-
intron boundaries were sequenced in
their entirety. Polymorphic variations in
the VEGFR3 gene were identified by
re-sequencing the gene from a
minimum of 50 chromosomes, and
allele frequencies were estimated from
the sequencing results. In order to
study EC specific transcription of
Vegfr3, sequences upstream of Vegfr3
gene were isolated. For in vitro
analysis, we used a downstream
reporter activation assay. Endothelial
and non-ECs were transfected with
constructs containing the luciferase
reporter gene driven by fragments of
the Vegfr3 upstream sequences. For in
vivo analysis, we used transgenic mice
with V e g f r 3 promoter regulated
expression of the LacZ marker gene.
These mice were analysed for β-
galactosidase expression to study
lymphat ic endothel ia l  speci f ic
expression of VEGFR-3.
2 Analysis of the lymphedema-linked mutant VEGFR-3s (II, III)
We used genetic linkage analysis and
direct sequencing to ident i fy
lymphedema-linked VEGFR3 missense
mutations in primary lymphedema
families. To test whether the single
amino acid substitutions identified alter
VEGFR-3 function we generated the
corresponding mutant receptor cDNAs
in a VEGFR3 expression vector, and
analysed their function in vitro in
transiently transfected cells and in
stable cell lines expressing the mutant
and/or WT receptors. The effect of the
mutations on tyrosyl phosphorylation of
VEGFR-3  was  s tud ied  by
immunoprecipitation and Western
blotting. In analyses of the turnover
time of mutant and WT receptors,
pulse-chase labeling experiments were
carried out. The effects of mutant
VEGFR-3 on downstream signaling
were studied using a transcriptional
reporter assay. An array of different
reporter vectors containing specific cis-
acting DNA enhancer elements
upstream of a luciferase reporter gene
were assayed.
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3 The Chy mouse model for human primary lymphedema (IV)
In order to study the role of inactivating
VEGFR3 mutations in vivo, we used
the Chy mouse model of lymphedema.
The  Chy  m ice  have  an
ethylnitrosourea-induced mutation
which has been linked to the Vegfr3
locus, on mouse chromosome 11 (Lyon
and Glenister, 1984; Lyon and
Glenister, 1986). By direct sequencing
we found that the Chy mice were
heterozygous for a Vegfr3 point
mutation (A3157T). This corresponds
to an I1053F substitution in the
VEGFR-3 tyrosine kinase domain. The
mouse and human receptors are highly
conserved and, as the expression
vector for mouse VEGFR-3 was not
available, the A3157T mutation was
generated in the human VEGFR-3
exp ress i on  vec to r .  Ty rosy l
phosphorylation of the mutant receptor
was analysed by transient transfection
and Western blotting. The phenotypic
features of lymphatic vessels in the
Chy mice were analysed using
immunoh i s tochem is t r y  ( IHC) ,
fluorescent microlymphography, and
MRI. The blood vessels were analysed
using platelet endothelial cell adhesion
molecule-1 (PECAM-1) IHC and
Lycopersicon esculentum l ec t in
staining.
4 Lymphedema therapy in the Chy model (IV)
Chy mice are heterozygous for the
VEGFR-3(I1053F) mutation and
therefore there remains some signaling
via the WT allele. Hence, we wanted to
analyse whether VEGFR-3 stimulation
with an excess of ligand is sufficient to
overcome lymphatic hypoplasia caused
by the mutant receptor. We explored
this possibility using both adenovirus
and AAV mediated VEGF-C gene
therapy in the skin of the Chy mice.
The effects of VEGF-C overexpression
were analysed by f luorescent
microlymphography and IHC. The
resu l ts  f rom v i ra l  VEGF-C
overexpression studies were further
confirmed by crossing the Chy mice
with mice expressing VEGF-C156S in
skin keratinocytes (Veikkola et al.,
2001).
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RESULTS AND DISCUSSION
The main results are briefly described here. The results are described and
discussed in more detail in the original publications.
1 The VEGFR3 genomic structure and regulatory region (I)
Previous studies have shown linkage of
congenital primary lymphedema to the
VEGFR3  region in chromosome 5q
(Evans et al., 1999; Ferrell et al., 1998;
Witte et al., 1998). In order to clarify
which mutations are associated with
lymphedema, we first resolved the
genomic structure of the V E G F R 3
gene. This gene was found to consist
of 31 exons, and its structure closely
resembles those of Vegfr1 and
VEGFR2 (Kondo et al., 1998; Yin et al.,
1998) (Fig. 8). Exons 30a and 30b of
the VEGFR3  gene are alternatively
spliced. In mice, only the longer isoform
exists (Pajusola et al., 1993), and
interestingly it was reported that the
shorter transcript in humans is the
result of a retroviral insertion (Hughes,
2001). This insertion may contribute to
diversity in VEGFR-3 signaling, as the
shorter form lacks three tyrosyl
residues, that are important in
downstream signaling (Fournier et al.,
1995; Fournier et al., 1996).
VEGFR3  exon-intron boundaries
were sequenced from cosmid
subclones, and the polymorphic single
base pair transversions within VEGFR3
were examined. We found 22
intragenic polymorphic variations, of
which four resulted in amino acid
substitutions (N149D, T494A, P641S
and R1146H). Phosphorylation of the
P641S mutant of VEGFR-3 was tested
in vitro, and it appeared to be
phosphorylated in a similar manner to
the WT receptor (Karkkainen et al.,
2000).
Figure 8. Location of the VEGFR3 polymorphisms and missense mutations. Genomic structure of
VEGFR3 consists of 31 exons, of which 30a and 30b are alternatively spliced. Above the genomic
structure is shown the VEGFR-3 domain structure, consisting of the signal sequence (ss), seven Ig
homology domains (Ig), a transmembrane domain TM and two tyrosine kinase domains (TK). Below the
exon structure are indicated the locations of the VEGFR3 polymorphisms and lymphedema-linked
amino acid substitutions (highlighted in grey). The introns are not drawn in scale.
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As VEGFR-3 is specifically expressed
on a lymphatic endothelium, the
regulatory region of VEGFR3  may
provide an important tool for molecular
biology in any attempt to target the
lymphatic system. On the other hand,
regulation of VEGFR-3 expression may
be affected in lymphatic disorders.
Thus, we wanted to analyse VEGFR3
promoter regions which mediate
LEC/EC specific expression, both in
cell cultures and in vivo. Two homology
regions (HRs) were found, which
showed 70% identity between mouse
and human VEGFR3  promoter
sequences.
The luciferase reporter assay
showed that the Vegfr3 promoter had
much stronger activity in ECs
compared with non-ECs. Progressive
5’-deletions were made to the promoter
to further characterize the sequences
critical for activity. Results using 3.0,
1.6, 0.8, and 0.5 kb promoter fragments
showed that the region upstream of the
HR1 contains inhibitory elements,
whereas the HR1 itself contains
transcriptional enhancer elements. The
cell culture experiments were carried
out using blood vascular ECs, because
no LEC lines were available at the time.
The LEC specificity of various
Vegfr3 promoter fragments was further
confirmed in transgenic mice. LacZ
expression was controlled by 3.6, 1.6,
or 0.8 kb promoter fragments, and
reporter gene expression was
compared to that of Vegfr3+/- mice at
E15.5, when the lymphatic vessels are
visible. The longer promoter fragments
induced LEC specific expression,
whereas LacZ expression driven by the
0.8 kb fragment was also seen in blood
vessels. Overall, staining was
visualized in only a subset of the
transgenic embryos, suggesting that
further regulatory/enhancer elements
may be located within the first intron of
the Vegfr3 gene. Such enhancers have
previously been reported within the
Vegfr2 and Tek genes (Kappel et al.,
1999; Schlaeger et al., 1997).
2 Analysis of the lymphedema-linked mutant VEGFR-3s (II, III)
2.1 Dominant negative effect of the mutant VEGFR-3s
As we had resolved the genomic
structure of VEGFR3, it now became
possible to identify the V E G F R 3
mutations in the Milroy’s disease
families. We found four new missense
mutations to add to the one published
previously (Ferrell et al., 1998). The
goal of this study was also to reveal the
mechanisms by which the mutant
VEGFR-3s result in a lymphedema
phenotype.
To test the properties of the mutant
VEGFR-3s, the corresponding
expression vectors were generated and
their phosphorylation was analysed in
transiently transfected cells. No tyrosyl
phosphorylation was detected in the
G857R, H1035R, R1041P, L1044P or
P1114L mutant proteins, indicating that
the lymphedema-linked mutations block
VEGFR-3 tyrosine kinase function. The
mutant receptors were kinase inactive
also in an autokinase assay (MK
unpublished data). Upon co-expression
of epitope-tagged WT and mutant
receptors in a transient transfection
system, the mutant protein did not
significantly quench phosphorylation of
the WT receptor. The WT and mutant
receptors formed heterodimers, and the
WT receptor  was ab le  to
transphosphorylate the mutant
receptor. The results were also
confirmed in a ligand-dependent
system.
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Figure 9. A model for mutant VEGFR-3 function in the lymphedema patients. The patients are
heterozygous for the mutant allele and, thus have three different types of VEGFR-3 dimers on the LEC
surface. Whereas the WT-WT dimers are internalized after activation, the dimers containing a mutant
receptor are not phosphorylated normally. These dimers seem to accumulate on the cell surface,
causing a dominant-negative effect and leading to hypoplasia of the lymphatic vessels in the patients.
As tyrosine kinase signaling is also
regulated via internalization of the
activated ligand-receptor complex
(Reviewed in Wiley and Burke, 2001),
we studied the turnover time of the
mutant and WT receptors by pulse-
chase analysis. The decay of WT
VEGFR-3 polypeptide was faster than
for the mutant receptors, indicating that
the mutant receptors were more stable
on the cell surface. These results
suggest that the activated WT receptor
is internalized, and degrades at a faster
rate than the mutant receptor, and that
the mutant receptor may accumulate
on the cell surface (Fig. 9).
Downstream signaling mediated by
WT and mutant receptors was
analysed using a transcriptional
reporter assay. An array of different
reporter constructs were tested, and
enhanced reporter expression after
VEGFR-3 stimulation was induced via
the AP-1 and NFκB transcription factor
complexes, but not via other elements
tested. In this assay, the ability of
VEGFR-3 to activate the AP-1 or NFκB
complexes decreased with increasing
mutant VEGFR-3 concentration,
consistent with the defective signaling
function of the mutant receptor.
Interestingly, it has recently been
suggested that lymphedema in the
EDA-ID (ectodermal dysplasia with
immunodeficiency) patients may be
caused by defective VEGFR-3
signaling via the NF-κB transcription
factor (Döffinger et al., 2001).
In contrast to the inactivating
missense mutations, VEGFR-3 haplo-
insufficiency probably doesn’t lead to
l y m p h e d e m a .  C h r o m o s o m a l
abnormalities involving deletion of the
VEGFR3 interval do not seem to result
in lymphedema (Barber et al., 1996;
Groen et al., 1998). This is compatible
with the result that Vegfr3-/- mice die
during embryogenesis due to a failure
of cardiovascular development, while
the heterozygotes have no obvious
phenotypic abnormality (Dumont et al.,
1998). However, this protection may
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depend on the genetic background of
the mice (T. Mäkinen et al.,
unpublished observations), indicating
that genetic factors may have an effect
on the appearance of lymphedema.
In conclusion, these results suggest
that the signaling via the lymphedema-
linked VEGFR-3s is defective. The
receptor encoded by the mutant allele
seems to act in a dominant negative
manner due to the accumulation of the
mutant receptor onto the LEC surface.
2.2 Interaction of VEGFR-3 with other pathways
Recent reports have revealed several
proteins which are important in the
formation of the lymphatic vasculature.
Integrin α9β1 seems to be required for
normal lymphatic development,
possibly in concert with VEGFR-3. The
first evidence of this was the report that
the α9-/- mice die 6-12 days after birth
due to severe chylothorax and resulting
respiratory failure (Huang et al., 2000).
Whereas β1 integrin is ubiquitously
expressed and forms dimers with
several α subunits, α9 integrin only
forms dimers with β1 integrin chains,
and is expressed only in a subset of
tissues, for example transiently in the
thoracic duct during embryogenesis.
Thus, α9β1 integrin appears to be
required for normal development of the
lymphatic system (Huang et al., 2000).
In addition, recent results indicate that
β1 integrin associates with VEGFR-3
and is able to induce its tyrosine
phosphorylation, albeit weakly (Wang
et al., 2001). The ECM proteins
(collagen and fibronectin) were able to
induce VEGFR-3 phosphorylation,
which was mediated by β1 integrin.
Both VEGFR-3 and β1 integrin
activation were required for cell
migration, while a lymphedema-linked
mutant VEGFR (G857R) did not induce
cell migration on collagen. These
results suggest co-operation between
β1 and VEGFR-3 signaling in cell
migration. Thus, it is possible that some
of the defects in lymphedema may be
as a result of impaired LEC migration.
Net, a member of the Ets-domain
transcription factor and ternary complex
factor families also has a role in the
development of the lymphatic system.
One function of Net is to repress
transcription of the immediate early
genes (c-fos, egr-1, and Jun-B) when
the mitogen-activated protein kinases
(MAPK) are not activated. Net is
expressed in the embryonic
vasculature, and its EC expression
persists during development (Ayadi et
al., 2001a). Net is co-localized with
VEGFR-3 in the thoracic duct, and the
lymphatic vessels of the intestine and
skin at E16.5 (Ayadi et al., 2001b).
Netδ/δ mice, which lack the DNA binding
domain die soon after birth because of
a chylothorax suggesting a possible
interaction in the signaling pathways of
Net and VEGFR-3 in lymphatic
endothelium (Ayadi et al., 2001b).
These results suggest that several
regulatory and structural proteins have
a role in the correct development of the
lymphatic vasculature. Further
knowledge of the interactions between
the different signaling pathways may
help in revealing the mechanisms of
lymphatic vessel development and
regulation.
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3 The Chy mouse model for human primary lymphedema (IV)
Since mutations within VEGFR3 are
likely to impair several cellular
processes, it is necessary to study the
role of VEGFR-3 in lymphedema by in
vivo methods. We have analysed the
pathogenesis of lymphedema using the
Chy mouse model.
The Chy mice ,  showing
accumulation of chylous fluid into the
abdomen, were generated by treating a
male mouse with ethylnitrosourea, and
screening the F1 generation for
lymphatic phenotypes (Reviewed in
Anderson, 2000). The mutation in the
Chy mouse line has been mapped to
chromosome 11 (Lyon and Glenister,
1984; Lyon and Glenister, 1986). We
sequenced the Vegfr3 candidate gene
of this chromosome in Chy mice
(Watkins-Chow et al., 1997) and found
an A3157T mutation resulting in an
I1053F substitution in the tyrosine
kinase domain of VEGFR-3. This
mutation is located in a highly
conserved catalytic domain of the
receptor, in close proximity to the
VEGFR-3 mutations in human primary
lymphedema (Irrthum et al., 2000;
Karkkainen et al., 2000).
It has been estimated that using the
ENU mutagenesis technique, each F1
animal is heterozygous for 100 new
inactivating mutations (Anderson,
2000). Thus, the presence of other
possible mutations affecting the Chy
phenotype cannot be ruled out.
However, the other mutations should
become segregated out during the
numerous generations of mice
screened in the course of maintaining
the Chy mouse strain. In addition, the
inactivating VEGFR3 mutations are
causative for human lymphedema, and
also the phenotypic features in the Chy
mice are likely to result from the Vegfr3
mutations.
Heterozygous Chy pups have
chylous fluid in the abdomen after
suckling, indicating possible defects in
the lymphatic system. In common with
human lymphedema patients, the limbs
of Chy mice are also swollen. In IHC
analysis, we found that the superficial
lymphatic vessels are hypoplastic in
Chy mice, whereas the intestinal
subserosal lymphatics are enlarged
when compared with WT mice.
Similarly, the pathology of primary
lymphedema is characterized by non-
functional (usually hypoplastic or
aplastic) superficial lymphatic vessels
(Kinmonth et al., 1957), and in some
rare human cases, lymphedema is
associated with accumulation of
chylous ascites and enlargement of the
subserosal lymphatic vessels (Lee and
Young, 1953; McKendry et al., 1957).
The molecular mechanisms of the
local defects in the lymphatic vessels in
lymphedema are not well known, but
one possible explanation is the regional
diversity of the lymphatic endothelium.
This hypothesis is supported by the
finding that inhibition of VEGFR-3
signaling in transgenic mice resulted in
transient loss of the lymphatic vessels,
but these vessels started to re-grow
after three postnatal weeks (Mäkinen et
al., 2001). However, there was no re-
growth of the skin lymphatics. Such a
result cannot be explained by K14-
promoter driven transgene expression,
because there are also ligand-
saturating levels of the transgene-
encoded protein in the bloodstream of
adult transgenic mice. Thus, it is
possible that VEGFR-3 signaling is
required for embryonic and early post-
natal development of the lymphatic
vessels, which then become mature or
resistant to loss of VEGFR-3 ligands
and use other signals to regenerate.
Some di f ferences in gene
expression within the lymphatic vessels
have been detected. For example,
podoplanin is expressed only in
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lymphatic capillaries devoid of a
smooth muscle layer (Breiteneder-
Geleff et al., 1999). A recent study
shows that the β-chemokine receptor
D6 is expressed only in the lymphatic
vessels of the skin and intestine and in
the lymph nodes (Nibbs et al., 2001). In
addition, the β-chemokine receptor D6
ligands bind to dermal afferent
lymphatic vessels (Hub and Rot, 1998).
Lymphatic vessels in both the skin
and in the intestine are located near the
surface of the body, in places that are
usually richly supplied with lymphatic
vessels. These “superficial” lymphatic
vessels function as an important
transport route for Langerhans cells or
DCs, which process pathogenic
antigens and carry them to the draining
lymph nodes. Chemokine binding to the
LECs may be involved in the process of
cell entry into the afferent lymphatic
vessels. Thus, the proteins needed for
this are expressed in sites where there
are a lot of lymphocytes and DC
trafficking into the lymphatic vessels.
One possible explanation for the
lack of lymphatic hypoplasia in the
visceral organs of the Chy mice is that
VEGF-C interacts with a second
receptor in these organs. Because
NRP-2 has been found to bind some of
the VEGF family members, we tested
whether it could be a receptor for
VEGF-C. In our studies, VEGF-C was
able to bind NRP-2. In addition,
VEGFR-3 was able to interact with the
NRP-2 receptor itself (MK, unpublished
data). Although no direct signaling via
NRP-2 has been detected, it may have
a role as a co-receptor, which may be
similar to what has been published
about NRP-1 and plexins (Takahashi et
al., 1999). One could speculate that
NRP-2 has a role in modulating
VEGFR-3 activity in cells where they
are co-expressed. To support this
hypothesis, we detected a strong NRP-
2 signal from the intestinal lymphatic
endothelium, but we did not detected
NRP-2 staining in the lymphatic vessels
of the skin. These results suggest that
there is a difference in the VEGF-C
receptor expression between the
affected and unaffected lymphatic
vessels, which may contribute to the
development of the lymphedema
phenotype.
Interestingly, Ang2 deficient mice
also have defects in the intestinal
lymphatic vessels (G Thurston, C Suri,
G Yancopoulos, personal comm.). In
common with Chy mice, the peritoneal
cavity of Ang2 KO mice is filled with
chylous ascites, and they exhibit
defects in the intestinal vasculature.
The lymphatic vessels of the skin are
also abnormal. Thus, Ang2 is also
needed for proper lymphat ic
development. These results again
suggest co-operation between the
VEGFR and Tie families in regulating
the ECs, and suggest that signaling via
both the VEGFR and Tie receptors is
required for proper development and
function of the lymphatic vessels.
4 Lymphedema therapy in the Chy model (IV)
As lymphedema patients, the Chy mice
have some VEGFR-3 activity due to the
WT Vegfr3 allele. We thus wanted to
analyse the possibility of using VEGF-C
overexpression as a therapeutic tool for
primary lymphedema. To explore this
opportunity, we infected the ears of the
Chy mice by intradermal injections of
adenoviruses or AAVs encoding VEGF-
C. Using either of these viruses, we
were able to induce the growth of
lymphatic vessels in the skin. The
newly formed vessels were also
functional as shown by the uptake of a
fluorescent dye into the collecting
lymphatic vessels.
For possible future applications, we
also confirmed that a VEGFR-3 specific
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ligand (VEGF-C156S) (Joukov et al.,
1998; Veikkola et al., 2001) is sufficient
for the induction of the growth of
lymphatic vessels in the Chy mice.
These results indicate that VEGFR-3
stimulation with an excess of its
specific ligand is sufficient to overcome
lymphatic hypoplasia caused by the
mutant Vegfr3 allele.
Where do the newly formed
lymphatic vessels originate from in the
Chy mice? The Chy mice show a lack
of lymphatic vessels in the skin,
although a few lymphatic vessels have
been detected in some of the mice.
Whole-mount staining also show that
there are some scattered LYVE-1
positive LECs in the skin, but no
organized lymphatic vasculature (G.
Thurston and MK, unpublished data).
Thus, it is possible that viral VEGF-C
stimulation induces proliferation of
these pre-existing LECs and the
formation of a functional lymphatic
vascular network. Alternatively, it is
tempting to speculate that bone-
marrow derived precursors might also
have a role in this process. It has been
sugges ted  tha t  mesoderma l
lymphangioblasts originating from the
somites can participate in the
development of the lymphatic
vasculature (Wilting et al., 2000). On
the other hand, it has been shown that
the angioblasts from the bone marrow
also contribute to the angiogenesis in
adults (Reviewed in Carmeliet and
Luttun, 2001), and a subset of these
cells express VEGFR-3 (S. Rafii and K.
Alitalo, unpublished data). Thus, it is
possible that lymphatic endothelial
precursors exist in adults and that
these cells may participate in the
lymphangiogenic processes upon
VEGF-C stimulation.
As VEGF-C gene therapy induced
the growth of new lymphatic vessels in
the Chy model, we speculated that
such a therapy could be used to treat
lymphedema. The treatment of
lymphedema should be local, but in
many cases lymphedema is detected in
large areas, e.g. in the lower limb.
Potential gene therapy for lymphedema
could involve the administration of
VEGFR-3 ligand in the affected sites or
transfer of remaining lymphatic tissue
from internal sites to affected skin,
combined with growth factor
administration. Alternatively, ex vivo
VEGF-C gene transfer into the
keratinocytes could be utilized in
attempts to induce the growth of the
cutaneous lymphat ic  vessels
(Christensen et al., 2001).
Yet, an important question is
whether the lymphatic vessels
stimulated by VEGF-C exhibit sufficient
drainage capacity to treat the swelling
associated with lymphedema. The
stability of the new lymphatic vessels
should also be carefully assessed, and
it is possible that long-term growth
factor expression is needed to maintain
the newly formed vessels. In patients
with Milroy’s disease, lymphedema is
already present after birth. Therefore,
the treatment should be started as
early as possible to avoid the
secondary changes associated with
lymphedema, such as fibrosis,
thickening of the skin, and cellulitis.
VEGF-C gene therapy should also
be evaluated very carefully, because
VEGF-C also binds VEGFR-2 on the
blood vascular endothelium and is
capable of stimulating vascular
permeability and, in some conditions,
angiogenesis (Cao et al., 1998; Joukov
et al., 1997). Because of the possible
complications due to tissue edema or
accelerated tumor angiogenesis, the
VEGFR-3 specific growth factor VEGF-
C156S (Joukov et al., 1998) would
therefore be a more attractive choice
for therapeutic applications. An
additional concern would be the fact
that tumor lymphangiogenesis has
been associated with enhanced lymph
node metastasis (Karpanen et al.,
2001; Mandriota et al., 2001; Skobe et
al., 2001a; Stacker et al., 2001). Thus,
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treatment of secondary lymphedema
arising after lymphadenectomy may
pose a problem, because it could
enhance the growth and spread of
dormant metastases. However, the
half-life of VEGF-C in the blood
circulation is short (Veikkola et al.,
2001) and local VEGF-C therapy is
thus likely to function without systemic
effects. In the studies of lymphedema
therapy, genetic mouse models such
as the Chy mice, will be beneficial and
essential.
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CONCLUDING REMARKS
During the past few years, researchers
have been able to answer some of the
questions about lymphatic vessel
formation and function, issues which
have been unknown for decades. Two
lymphangiogenic molecules, VEGF-C
and VEGF-D have been identified, and
their signaling via VEGFR-3 has been
shown to induce lymphangiogenesis.
Some other proteins, such as
transcription factor Prox1, and cell
surface proteins LYVE-1 and
Podoplanin have also been found to be
involved in regulation and function of
the lymphatic vessels, although their
exact functions are not yet known.
During embryogenesis, VEGF-C
becomes restricted to cells adjacent to
VEGFR-3 posi t ive endothel ia,
suggesting paracrine VEGF-C/VEGFR-
3 signaling as a mediator of
lymphangiogenesis. In vivo studies
have also indicated that VEGFR-3
s igna l i ng  i s  su f f i c i en t  f o r
lymphangiogenic response. In
lymphedema, the normal development
or function of the lymphatic vessels is
disturbed, resulting in hypoplastic
subcutaneous lymphatic network, and
accumulation of fluid into the
extremities. Lymphedema is a chronic,
disfiguring and disabling condition that
has mainly been treated by manual
lymphatic drainage and by compressive
carments.
We have shown that disturbed
VEGFR-3 signaling results in hereditary
lymphedema in some families. We
have also described the Chy mouse
model for Milroy’s disease with swelling
of the limbs due to a inactivating Vegfr3
mutation. Using the Chy mice, we have
shown that a potential gene therapy for
lymphedema may involve the
administration of VEGF-C or VEGF-D
to patients who have insufficient
VEGFR-3 signaling. Another possibility
is to transfer remaining lymphatic tissue
from internal sites to affected skin,
combined with growth factor
administration. Interesting recent
evidence indicates that there may be
EC progenitors circulating in the blood,
and lymphatic endothelial precursor
cells have been detected in avian
embryos (Schneider et al., 1999). Such
cells would provide an important tool
for the further development of cell and
gene based therapies for lymphedema.
Our results suggest that VEGFR-3
ligand administration alone or in
c o m b i n a t i o n  w i t h  o t h e r
lymphangiogenic factors could be a
powerful tool in the therapy of various
forms of human lymphedema. It also
gives a paradigm for treatments of
other diseases associated with mutant
RTKs.
The identification of other crucial
modifying factors in the process of
lymphangiogenesis will be the next
challenge in lymphatic research. This
research may be facilitated by the
finding that LECs can be separated
from the blood vascular ECs (Kriehuber
et al., 2001; Mäkinen et al., 2001).
Dif ferential  gene and protein
expression between blood vascular
ECs and LECs can now be analysed in
detail. In addition, it may be possible to
isolate LECs from lymphedema
patients in order to gain a more
detailed knowledge of the molecular
mechanisms of lymphedema, and to
develop more targeted therapies for
this disease. These methods probably
help us in understanding the
pathogenesis of different diseases in
which lymphatic vessels are involved.
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